FLC Capital Advisors Has $2.10 Million Position in Johnson & Johnson $JNJ

Key Points

• FLC Capital Advisors increased its position in Johnson & Johnson by 16.8% during the second quarter, owning 13,769 shares valued at approximately $2.1 million.
• Johnson & Johnson announced a quarterly dividend of $1.30, set to be paid on December 9th, representing an annualized yield of 2.7%.
• Recent analyst ratings for Johnson & Johnson include price target increases and a consensus rating of "Moderate Buy."

FLC Capital Advisors grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 16.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,769 shares of the company's stock after purchasing an additional 1,982 shares during the quarter. FLC Capital Advisors' holdings in Johnson & Johnson were worth $2,103,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Ellis Investment Partners LLC lifted its stake in shares of Johnson & Johnson by 0.7% in the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company's stock valued at $1,307,000 after buying an additional 62 shares during the period. Cypress Wealth Services LLC lifted its stake in shares of Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company's stock valued at $1,013,000 after buying an additional 62 shares during the period. Horizon Bancorp Inc. IN lifted its stake in shares of Johnson & Johnson by 11.2% in the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company's stock valued at $97,000 after buying an additional 64 shares during the period. Global Strategic Investment Solutions LLC lifted its stake in shares of Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company's stock valued at $294,000 after buying an additional 65 shares during the period. Finally, JSF Financial LLC lifted its stake in shares of Johnson & Johnson by 2.2% in the second quarter. JSF Financial LLC now owns 2,993 shares of the company's stock valued at $457,000 after buying an additional 65 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.3%

Shares of JNJ opened at $193.78 on Tuesday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The company has a 50-day moving average price of $180.89 and a two-hundred day moving average price of $165.18. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market cap of $466.68 billion, a price-to-earnings ratio of 18.70, a P/E/G ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The company had revenue of $24.02 billion during the quarter. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson's payout ratio is 50.19%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on JNJ. Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a "market perform" rating in a research note on Monday, October 6th. Raymond James Financial increased their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an "outperform" rating in a research note on Wednesday, October 15th. Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Weiss Ratings upgraded shares of Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a "hold" rating in a research note on Wednesday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $200.06.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.